Stock listing

NASDAQ:DRTS Alpha Tau Medical Ltd Stock

Home listing (NASDAQ) of Alpha Tau Medical Ltd

Follow Alpha Tau Medical Ltd into a list and get an email when it puts out news.

Share price · NASDAQ:DRTS

$11.76 USD -0.25 (-2.1%)

Close on Nov 20, 2026

Past year +238.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$11.32 – $12.19 USDNov 20, 2026
Volume
626,868 sharesNov 20, 2026
Market cap
$1.09B USDAt the close on Nov 20, 2026 · price × 92.48M shares outstanding
52-week range
$3.43 – $15.79 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$8.02M USDMedian day 467,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Alpha Tau Medical Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DRTS · Home$11.76 USD-0.255 (-2.1%)626,868$11.47$12.19$11.32$12.01Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DRTS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$11.76-0.255-2.1%$11.47$12.19$11.32626,868
$12.01-0.08-0.7%$12.05$12.22$11.82640,029
$12.09+0.12+1.0%$12.00$12.30$11.671,077,732
$11.97-1.41-10.5%$14.40$14.41$11.812,286,815
$13.38+0.02+0.1%$13.45$13.49$12.98403,519
$13.36-0.66-4.7%$13.92$13.92$13.15611,186
$14.02+0.32+2.3%$14.00$14.59$14.00833,549
$13.70-0.41-2.9%$13.90$14.17$13.60426,928
$14.11+0.39+2.8%$13.99$14.43$13.80494,895
$13.72+0.42+3.2%$13.51$13.98$13.16417,324
$13.30-0.73-5.2%$13.93$13.98$12.99671,648
$14.03+0.49+3.6%$13.85$14.20$13.59685,874
$13.54+0.71+5.5%$13.07$13.63$13.07662,011
$12.83-0.23-1.8%$13.22$13.23$12.67436,732
$13.06-0.17-1.3%$12.85$13.15$12.74475,222
$13.23-0.12-0.9%$13.31$13.55$13.06282,833
$13.35-0.16-1.2%$13.51$13.61$13.27401,163
$13.51+0.62+4.8%$12.99$13.66$12.71341,843
$12.89-0.27-2.1%$13.18$13.56$12.77379,003
$13.16+0.26+2.0%$12.75$13.25$12.70324,175
$12.90-0.58-4.3%$13.25$13.46$12.71447,711
$13.48+0.39+3.0%$13.47$13.85$13.30500,316
$13.09+0.47+3.7%$12.61$13.38$12.50833,535
$12.62+0.33+2.7%$12.56$12.81$12.42688,391
$12.29-0.87-6.6%$13.24$13.30$11.99778,700
$13.16-0.34-2.5%$13.14$13.47$13.02620,300
$13.50-0.24-1.7%$13.48$13.79$13.34422,000
$13.74-0.52-3.6%$14.11$14.25$13.65484,600
$14.26-0.15-1.0%$14.42$14.44$14.11281,500
$14.41+0.41+2.9%$14.00$14.50$13.98368,000
$14.00-0.25-1.8%$14.17$14.30$13.56595,200
$14.25-0.23-1.6%$14.27$14.44$14.10466,300
$14.48-0.41-2.8%$14.98$15.02$14.40427,400
$14.89+0.12+0.8%$14.85$15.04$14.68342,400
$14.77+0.26+1.8%$14.73$14.91$14.64307,100
$14.51-0.40-2.7%$14.74$14.97$14.32379,900
$14.91-0.28-1.8%$15.14$15.34$14.88368,900
$15.19+0.15+1.0%$15.00$15.30$14.77513,900
$15.04+0.50+3.4%$14.54$15.20$14.39397,400
$14.54-0.23-1.6%$14.90$14.92$14.39435,400
$14.77+0.25+1.7%$14.50$14.80$14.31467,000
$14.52-0.62-4.1%$15.09$15.25$14.31727,000
$15.14-0.36-2.3%$15.38$15.45$15.05360,400
$15.50+0.26+1.7%$15.48$15.59$15.10411,400
$15.24-0.25-1.6%$15.60$15.63$15.10624,200
$15.49+0.45+3.0%$15.15$15.79$15.01858,700
$15.04+0.17+1.1%$14.88$15.20$14.73671,000
$14.87+0.47+3.3%$14.30$15.00$14.20411,600
$14.40-0.03-0.2%$14.11$14.84$14.11388,000
$14.43-0.01-0.1%$14.49$14.62$14.01410,400
$14.44+0.17+1.2%$14.04$14.81$13.80457,200
$14.27-0.57-3.8%$14.70$14.84$14.27412,000
$14.84-0.19-1.3%$15.03$15.08$14.47561,500
$15.03+0.41+2.8%$14.69$15.17$14.43749,300
$14.62+0.29+2.0%$15.00$15.07$14.32629,700
$14.33+0.37+2.7%$14.25$14.65$13.88372,500
$13.96-0.15-1.1%$13.96$14.40$13.65464,800
$14.11-0.53-3.6%$14.69$15.00$14.053,115,700
$14.64-0.17-1.1%$14.76$14.90$14.45475,300
$14.81-0.15-1.0%$14.83$15.10$14.75474,500
$14.96+0.26+1.8%$14.70$15.00$14.58432,500
$14.700.000.0%$14.74$14.98$14.50495,000
$14.70-0.22-1.5%$14.93$15.00$14.57483,400
$14.92+0.56+3.9%$14.57$15.02$14.40626,200
$14.36-0.11-0.8%$14.47$14.60$14.20349,200
Ticker
NASDAQ:DRTS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Alpha Tau Medical Ltd news

Alpha Tau Medical Ltd on 6ix

Sector
Health care
Industry
Biotechnology
News releases
35 in the last 12 months · 50 in all · newest Nov 19, 2026 · oldest 2025
Decks
9 decks · latest Nov 16, 2026

Where Alpha Tau Medical Ltd is listed

ListingExchangeCountryCurrency
NASDAQ:DRTS · Home listing · This pageNASDAQUnited StatesUSD
TASE:DRTSTASEIsraelILA
BOATS:DRTSBOATSUnited StatesUSD

Valuation

Price/book 55.3× against a median of 2.6×: 10th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.00B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
55.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.8×
Beta vs S&P 500
1.89

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Alpha Tau Medical Ltd · NASDAQ:DRTSUS$1.09BUS$1.00Bn/an/an/a55.3×n/a0.8×1.89
Structure Therapeutics, Inc. · NASDAQ:GPCRUS$1.15B−US$82.92Mn/an/an/a0.9×n/a0.0×1.38
COMPASS Pathways Plc · NASDAQ:CMPSUS$1.14BUS$747.8Mn/an/an/a8.0×n/a0.4×1.65
Ascentage Pharma Group International · HKEX:6855US$1.11BUS$1.14Bn/a13.7×n/a13.4×−216.5%3.8×n/a
Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321US$1.10BUS$1.10B102×6.8×n/a2.9×6.6%0.5×n/a
Pharma Mar SA · BME:PHMUS$1.10BUS$978.5M14.6×3.8×16.6×4.2×28.8%0.3×n/a
Kardigan, Inc. · NASDAQ:KARDUS$1.08BUS$621.1Mn/an/an/a1.9×n/a0.0×n/a
PYC Therapeutics Limited · ASX:PYCUS$1.07BUS$775.8Mn/an/an/a2.3×n/a0.0×n/a
Jade Biosciences, Inc. · NASDAQ:JBIOUS$1.06BUS$583.6Mn/an/an/a2.3×n/a0.0×1.14
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Nektar Therapeutics · NASDAQ:NKTRUS$1.03BUS$492.8Mn/a9.4×n/a1.2×−339.7%0.1×1.28
Median of the othersUS$1.09BUS$761.8M58.5×9.4×16.6×2.6×−128.9%0.2×1.33

Forecasts

3 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
21.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.24 · 3 analysts

Team and board

Officers

OfficerRole
Uzi SoferCEO & Chairman
Raphi LevyChief Financial Officer
Amnon GatChief Operations Officer
Robert DenChief Medical Officer
Ronen SegalChief Technology Officer
Yona KeisariChief Scientific Officer & Co-Inventor

Board

DirectorRole
Uzi SoferCEO & Chairman
Alan AdlerDirector
David M. MilchDirector
Maya NetserDirector
Michael AvruchDirector
Morry BlumenfeldDirector
Nadav KidronDirector
Ruth AlonDirector

Events

QuarterResultsShare move
Q3 2026Nov 19, 2026 · After close−2.1%
Q2 2026Aug 10, 2026 · After close+4.9%
Q1 2026May 18, 2026 · After close+6.5%
Q4 2025Mar 5, 2026−8.7%
Q3 2025Nov 20, 2025 · After close+10.1%
Q2 2025Aug 11, 2025 · After close−8.7%
Q1 2025May 19, 2025 · After close+5.2%
Q4 2024Mar 12, 2025+0.8%
Q3 2024Nov 19, 2024 · After close−0.2%
Q2 2024Aug 14, 2024 · After close+6.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 20, 2024 · After close0.0%
Q4 2023Mar 7, 2024 · After close−0.7%
Q3 2023Nov 16, 2023 · After close+4.1%
Q2 2023Aug 28, 2023 · After close+3.1%
Q1 2023May 23, 2023 · After close+3.5%
Q4 2022Mar 9, 2023 · After close−1.5%
Q3 2022Nov 22, 2022 · After close+3.2%
Q2 2022Aug 25, 2022 · After close+1.7%
Q1 2022May 26, 2022 · After close+4.4%
Q4 2021Mar 28, 2022 · Before open+6.6%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update28 slidesNov 16, 2026
Investor Presentation (August 2026)Investor deck41 slidesAug 22, 2026
Technical Presentation (May 2026)Technical52 slidesMay 2026
Investor Presentation (March 2026)Investor deck37 slidesMar 9, 2026
J.P. Morgan Healthcare Conference 2026Conference34 slidesJan 5, 2026
Investor Day (January 2025)Investor day84 slidesJanuary 2025
Investor Presentation (July 2022)Investor deck68 slidesJul 18, 2022
SPAC Merger (January 2022)SPAC merger35 slidesJan 12, 2022
SPAC Merger (July 2021)SPAC merger40 slidesJul 8, 2021

Open Decks

Financings

RaiseDate
Registered direct offering of ordinary shares
Closed: US$36.9M raised · US$2.612 a share
Buyers: Oramed Pharmaceuticals Inc. (affiliate) (14,110,121 ordinary shares at $2.612 per share)
Use of proceeds: General corporate purposes, including R&D for product candidates, expanding manufacturing capabilities and potential commercialization
Apr 28, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue1.23M1.10M1.07M979.0K776.0K86.0K
Gross profit-1.23M-1.10M-1.07M-979.0K-776.0K-86.0K
Research and development32.1M27.0M26.4M20.9M11.4M7.54M6.64M
Selling, general and administrative8.36M6.67M7.33M10.3M1.86M1.41M977.0K
Operating income-42.3M-36.0M-35.7M-32.1M-13.8M-9.24M8.01M
Depreciation and amortization1.23M1.10M1.07M979.0K776.0K86.0K66.0K
EBITDA-41.1M-34.9M-34.6M-31.2M-13.0M-9.16M8.08M
Interest expense347.0K303.0K75.0K1.77M12.7M217.0K1.28M
Income before tax-42.5M-31.7M-29.1M-33.7M-27.3M-8.72M8.32M
Income tax121.0K6.00K16.0K20.0K7.00K158.0K-146.0K
Net income-42.6M-31.8M-29.2M-33.8M-27.3M-8.88M-8.37M
Earnings per share, basic-0.53-0.45-0.42-0.53-0.67-0.22-0.25
Earnings per share, diluted-0.53-0.45-0.42-0.53-0.67-0.22-0.25

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents12.2M13.7M12.7M5.84M23.2M15.6M1.84M
Short-term investments60.9M45.9M69.1M98.7M8.08M30.4M26.3M
Receivables336.0K332.0K344.0K32.0K480.0K477.0K141.0K
Inventory-19.0K-1.06M-8.17M-29.8M1.13M
Current assets78.3M64.2M85.8M106.5M32.6M47.5M29.8M
Property, plant and equipment19.7M13.9M12.8M7.47M7.55M5.39M1.71M
Total assets105.7M86.2M107.4M120.1M42.2M53.0M31.6M
Accounts payable3.87M3.53M2.57M1.42M1.20M964.0K893.0K
Current liabilities10.5M8.68M7.10M4.34M4.41M2.09M1.35M
Long-term debt6.35M5.56M5.61M
Total debt13.7M12.5M13.3M5.19M54.0M54.0M
Total liabilities28.6M23.5M22.9M14.5M23.0M7.45M31.8M
Shareholders' equity77.1M62.7M84.5M105.7M-34.8M-8.43M-193.0K
Shares outstanding88.0M70.4M69.7M69.1M40.5M40.4M69.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-26.7M-19.8M-18.0M-23.9M-11.8M-7.25M-6.91M
Capital spending-6.08M-2.24M-6.40M-904.0K-2.93M-3.77M-1.29M
Free cash flow-32.8M-22.0M-24.4M-24.8M-14.7M-11.0M-8.20M
Cash from investing-20.6M20.8M18.7M-89.9M19.3M-7.82M-10.2M
Cash from financing45.8M25.0K5.30M96.9M111.0K29.3M5.32M
Change in cash-1.52M1.07M5.97M-17.2M7.68M14.3M-11.8M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 19, 2026Current reportSEC
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
6-K · Report of a foreign issuerNov 12, 2026Current reportSEC
6-K · Report of a foreign issuerOct 29, 2026Current reportSEC
6-K · Report of a foreign issuerOct 22, 2026Current reportSEC
6-K · Report of a foreign issuerOct 19, 2026Current reportSEC
6-K · Report of a foreign issuerAug 31, 2026Current reportSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
144 · Notice of proposed saleAug 21, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 12, 2026Insider tradeSEC
6-K · Report of a foreign issuerAug 10, 2026Current reportSEC
6-K · Report of a foreign issuerAug 10, 2026Current reportSEC
6-K · Report of a foreign issuerJul 21, 2026Current reportSEC
6-K · Report of a foreign issuerJul 15, 2026Current reportSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
6-K · Report of a foreign issuerJun 25, 2026Current reportSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 23, 2026Current reportSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
6-K · Report of a foreign issuerJun 11, 2026Current reportSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
6-K · Report of a foreign issuerJun 3, 2026Current reportSEC
6-K · Report of a foreign issuerJun 1, 2026Current reportSEC
6-K · Report of a foreign issuerMay 18, 2026Current reportSEC
6-K · Report of a foreign issuerMay 18, 2026Current reportSEC
6-K · Report of a foreign issuerMay 11, 2026Current reportSEC
6-K · Report of a foreign issuerMay 11, 2026Current reportSEC
6-K · Report of a foreign issuerMay 8, 2026Current reportSEC
6-K · Report of a foreign issuerMay 8, 2026Current reportSEC
6-K · Report of a foreign issuerMay 7, 2026Current reportSEC
6-K · Report of a foreign issuerMay 5, 2026Current reportSEC
6-K · Report of a foreign issuerMay 4, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMay 4, 2026Other filingsSEC
CORRESP · Letter to the SECApr 30, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 30, 2026Other filingsSEC
F-3 · Registration statementApr 27, 2026Offer documentSEC
6-K · Report of a foreign issuerApr 27, 2026Current reportSEC
6-K · Report of a foreign issuerApr 23, 2026Current reportSEC
6-K · Report of a foreign issuerMar 31, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 9, 2026Offer documentSEC
6-K · Report of a foreign issuerMar 9, 2026Current reportSEC
20-F · Annual reportMar 9, 2026Annual reportSEC
144 · Notice of proposed saleFeb 26, 2026Other filingsSEC
6-K · Report of a foreign issuerFeb 24, 2026Current reportSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
6-K · Report of a foreign issuerJan 29, 2026Current reportSEC
144 · Notice of proposed saleJan 14, 2026Other filingsSEC
144 · Notice of proposed saleJan 12, 2026Other filingsSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
144 · Notice of proposed saleJan 9, 2026Other filingsSEC
6-K · Report of a foreign issuerJan 6, 2026Current reportSEC
6-K · Report of a foreign issuerJan 5, 2026Current reportSEC
6-K · Report of a foreign issuerDec 18, 2025Current reportSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
6-K · Report of a foreign issuerDec 9, 2025Current reportSEC
6-K · Report of a foreign issuerDec 4, 2025Current reportSEC
6-K · Report of a foreign issuerDec 2, 2025Current reportSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
6-K · Report of a foreign issuerNov 20, 2025Current reportSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
6-K · Report of a foreign issuerOct 21, 2025Current reportSEC
144 · Notice of proposed saleOct 1, 2025Other filingsSEC
6-K · Report of a foreign issuerSep 2, 2025Current reportSEC
6-K · Report of a foreign issuerAug 27, 2025Current reportSEC
6-K · Report of a foreign issuerAug 11, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 24, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJul 3, 2025Other filingsSEC
CORRESP · Letter to the SECJun 30, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 27, 2025Other filingsSEC
F-3 · Registration statementJun 23, 2025Offer documentSEC
6-K · Report of a foreign issuerJun 17, 2025Current reportSEC
6-K · Report of a foreign issuerMay 28, 2025Current reportSEC
6-K · Report of a foreign issuerMay 19, 2025Current reportSEC
6-K · Report of a foreign issuerMay 13, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
6-K · Report of a foreign issuerMay 6, 2025Current reportSEC
SCHEDULE 13D · Big-stake noticeMay 1, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerApr 28, 2025Current reportSEC
424B5 · ProspectusApr 28, 2025Offer documentSEC
6-K · Report of a foreign issuerApr 2, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 12, 2025Offer documentSEC
6-K · Report of a foreign issuerMar 12, 2025Current reportSEC
20-F · Annual reportMar 12, 2025Annual reportSEC
6-K · Report of a foreign issuerFeb 27, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 24, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2025Current reportSEC
6-K · Report of a foreign issuerJan 27, 2025Current reportSEC
6-K · Report of a foreign issuerDec 18, 2024Current reportSEC
6-K · Report of a foreign issuerDec 17, 2024Current reportSEC
6-K · Report of a foreign issuerDec 17, 2024Current reportSEC
6-K · Report of a foreign issuerDec 11, 2024Current reportSEC
6-K · Report of a foreign issuerDec 6, 2024Current reportSEC
6-K · Report of a foreign issuerNov 19, 2024Current reportSEC
6-K · Report of a foreign issuerNov 13, 2024Current reportSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerOct 21, 2024Current reportSEC
6-K · Report of a foreign issuerOct 10, 2024Current reportSEC
6-K · Report of a foreign issuerSep 20, 2024Current reportSEC
6-K · Report of a foreign issuerAug 22, 2024Current reportSEC
6-K · Report of a foreign issuerAug 14, 2024Current reportSEC
6-K · Report of a foreign issuerAug 14, 2024Current reportSEC
6-K · Report of a foreign issuerJun 25, 2024Current reportSEC
6-K · Report of a foreign issuerMay 21, 2024Current reportSEC
6-K · Report of a foreign issuerMay 20, 2024Current reportSEC
6-K · Report of a foreign issuerMay 13, 2024Current reportSEC
6-K · Report of a foreign issuerMay 6, 2024Current reportSEC
6-K · Report of a foreign issuerMay 1, 2024Current reportSEC
6-K · Report of a foreign issuerMar 25, 2024Current reportSEC
144 · Notice of proposed saleMar 15, 2024Other filingsSEC
S-8 · Registration statement for employee plansMar 7, 2024Offer documentSEC
6-K · Report of a foreign issuerMar 7, 2024Current reportSEC
20-F · Annual reportMar 7, 2024Annual reportSEC
6-K · Report of a foreign issuerFeb 26, 2024Current reportSEC
6-K · Report of a foreign issuerDec 20, 2023Current reportSEC
144 · Notice of proposed saleDec 18, 2023Other filingsSEC
6-K · Report of a foreign issuerNov 29, 2023Current reportSEC
6-K · Report of a foreign issuerNov 28, 2023Current reportSEC
6-K · Report of a foreign issuerNov 20, 2023Current reportSEC
6-K · Report of a foreign issuerNov 16, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
6-K · Report of a foreign issuerOct 30, 2023Current reportSEC
6-K · Report of a foreign issuerOct 24, 2023Current reportSEC
6-K · Report of a foreign issuerSep 27, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveSep 25, 2023Other filingsSEC
CORRESP · Letter to the SECSep 20, 2023Other filingsSEC
UPLOAD · Letter from the SECSep 19, 2023Other filingsSEC
6-K · Report of a foreign issuerSep 14, 2023Current reportSEC
F-3 · Registration statementSep 11, 2023Offer documentSEC
6-K · Report of a foreign issuerAug 28, 2023Current reportSEC
6-K · Report of a foreign issuerAug 28, 2023Current reportSEC
6-K · Report of a foreign issuerAug 24, 2023Current reportSEC
6-K · Report of a foreign issuerAug 17, 2023Current reportSEC
6-K · Report of a foreign issuerAug 2, 2023Current reportSEC
144 · Notice of proposed saleJun 9, 2023Other filingsSEC
144 · Notice of proposed saleJun 8, 2023Other filingsSEC
144 · Notice of proposed saleJun 8, 2023Other filingsSEC
144 · Notice of proposed saleJun 6, 2023Other filingsSEC
6-K · Report of a foreign issuerJun 6, 2023Current reportSEC
144 · Notice of proposed saleJun 2, 2023Other filingsSEC
6-K · Report of a foreign issuerMay 24, 2023Current reportSEC
6-K · Report of a foreign issuerMay 23, 2023Current reportSEC
6-K · Report of a foreign issuerMay 3, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveApr 14, 2023Other filingsSEC
424B3 · ProspectusApr 13, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 12, 2023Other filingsSEC
CORRESP · Letter to the SECApr 11, 2023Other filingsSEC
UPLOAD · Letter from the SECApr 10, 2023Other filingsSEC
6-K · Report of a foreign issuerApr 3, 2023Current reportSEC
POS AM · Amendment to an effective registrationApr 3, 2023Offer documentSEC
F-3 · Registration statementApr 3, 2023Offer documentSEC
6-K · Report of a foreign issuerMar 29, 2023Current reportSEC
20-F/A · Annual report, amendedMar 23, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 13, 2023Current reportSEC
S-8 · Registration statement for employee plansMar 9, 2023Offer documentSEC
424B3 · ProspectusMar 9, 2023Offer documentSEC
6-K · Report of a foreign issuerMar 9, 2023Current reportSEC
20-F · Annual reportMar 9, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 8, 2023Current reportSEC
6-K · Report of a foreign issuerMar 3, 2023Current reportSEC
6-K · Report of a foreign issuerMar 1, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 21, 2023Current reportSEC
6-K · Report of a foreign issuerDec 13, 2022Current reportSEC
424B3 · ProspectusNov 22, 2022Offer documentSEC
6-K · Report of a foreign issuerNov 22, 2022Current reportSEC
6-K · Report of a foreign issuerNov 9, 2022Current reportSEC
6-K · Report of a foreign issuerNov 2, 2022Current reportSEC
6-K · Report of a foreign issuerOct 21, 2022Current reportSEC
6-K · Report of a foreign issuerSep 28, 2022Current reportSEC
EFFECT · Notice that a registration is effectiveSep 14, 2022Other filingsSEC
6-K · Report of a foreign issuerSep 8, 2022Current reportSEC
POS AM · Amendment to an effective registrationSep 6, 2022Offer documentSEC
6-K · Report of a foreign issuerSep 1, 2022Current reportSEC
6-K · Report of a foreign issuerAug 30, 2022Current reportSEC
6-K · Report of a foreign issuerAug 25, 2022Current reportSEC
6-K · Report of a foreign issuerAug 22, 2022Current reportSEC
6-K · Report of a foreign issuerJul 18, 2022Current reportSEC
6-K · Report of a foreign issuerJul 5, 2022Current reportSEC
6-K · Report of a foreign issuerJun 22, 2022Current reportSEC
6-K · Report of a foreign issuerJun 16, 2022Current reportSEC
6-K · Report of a foreign issuerJun 8, 2022Current reportSEC

This page holds 200 of 243 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Alpha Tau Medical Ltd’s releases · as of Sep 30, 2026

Common shares
92,478,154
Fully diluted
92,478,154

Fully diluted

LineSharesAs of
Common shares92,478,154Sep 30, 2026

Share count over time

CountShares
Nov 22, 202692,478,154
Sep 30, 202693,084,841

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
ARK Israel Innovative Technology ETF184KUS$2.17MJul 31, 2026
Adara Smaller Companies Fund83,091US$900KMay 31, 2026
Dunham Small Cap Growth Fund71,660US$845KJul 31, 2026
Fidelity Nasdaq Composite Index Fund53,399US$578KMay 31, 2026
Even Herd Long Short ETF24,657US$310KJun 30, 2026
Timber Point Global Allocations Fund20,000US$252KJun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Levy Raphi
Officer: Chief Financial Officer
Sale2,871USD 15.00US$43,065Aug 21, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale17,730USD 14.00US$248KAug 11, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale2,270USD 14.00US$31,780Jul 6, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale17,873USD 13.00US$232KJul 2, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale2,127USD 13.02US$27,694Jul 1, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale20,000USD 12.00US$240KJun 30, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale4,222USD 11.00US$46,442Jun 25, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale15,778USD 11.00US$174KJun 25, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale15,000USD 9.47US$142KJun 23, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale2,500USD 10.00US$25,000Jun 23, 2026
All 12 trades
TradeTradeSharesPriceValueDate
Levy Raphi
Officer: Chief Financial Officer
Sale17,500USD 10.90US$191KJun 3, 2026
Levy Raphi
Officer: Chief Financial Officer
Sale15,000USD 10.76US$161KJun 3, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Nadav Kidron
Other companies: Nano Dimension Ltd (Director · Since at least Aug 16, 2026); Lifeward Ltd. (Director · Since at least Mar 25, 2026); Oramed Pharmaceuticals Inc. (President and CEO, Director · Since at least Feb 3, 2006)
Director · Since at least May 12, 2025
Alan AdlerDirector · Since at least Nov 5, 2026
Amnon GatChief Operations Officer · Since at least Nov 5, 2026
David M. MilchDirector · Since at least Mar 18, 2026
Maya NetserDirector · Since at least Mar 18, 2026
Michael AvruchDirector · Since at least Nov 5, 2026
Morry BlumenfeldDirector · Since at least Mar 18, 2026
Raphi LevyChief Financial Officer · Since at least Aug 25, 2026
Robert DenChief Medical Officer · Since at least Oct 19, 2026
Ronen SegalChief Technology Officer · Since at least Nov 5, 2026
All 13 people
PersonSeat
Ruth AlonDirector · Since at least Nov 5, 2026
Uzi SoferCEO & Chairman · Since at least Mar 18, 2026
Yona KeisariChief Scientific Officer & Co-Inventor · Since at least Oct 22, 2026

Open People

Log in to ask 6ix AI your own questions about Alpha Tau Medical Ltd.